🇺🇸 FDA
Pipeline program

Lutikizumab, Placebo of Lutikizumab

M20-465

Phase 3 small_molecule active

Quick answer

Lutikizumab, Placebo of Lutikizumab for Hidradenitis Suppurativa is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie Deutschland GmbH & Co. KG
Indication
Hidradenitis Suppurativa
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials